FDAsafety guidance66% confidence
FDA AP — TECVAYLI (SUPPL)
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Janssen Biotech; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Application BLA761291. Sponsor: JANSSEN BIOTECH. Submission status: AP. Submission type: SUPPL. Review priority: N/A. Active ingredients: TECLISTAMAB-CQYV.
Supporting Context
- Therapeutic area
- Oncology · Monoclonal Antibody
- Sub-indication
- General
Related signal: FDA Accepts Supplement Application for DARZALEX by Janssen Biotech